Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Christopher Lieu, MD
Criterium Inc., d.b.a. Academic GI Cancer Consortium (AGICC)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
- University of Colorado Cancer Center
Aurora, Colorado, United States
- Yale University, Yale Cancer Center
New Haven, Connecticut, United States
- Laura & Isaac Permutter Cancer Center at Nyu Langone
New York, New York, United States
- the Ohio State University, James Cancer Hospital
Columbus, Ohio, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2015
- Primary completion
- 29 Mar 2018
- Completion
- 29 Mar 2018
- Last update posted
- 2 Apr 2018
- Registered enrollment
- 4
- Registry id
- NCT02638909
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.